French drugmaker Sanofi on Monday flagged another delay to a U.S. regulatory decision for its experimental multiple sclerosis ...

Sanofi’s multiple sclerosis hopeful tolebrutinib faced dual setbacks on Monday, with a late-stage failure in one form of the ...

A U.S. regulatory decision on tolebrutinib will again be delayed while a late-stage trial of the drug for a different form of ...

Sanofi will not be pursuing approval of tolebrutinib for PPMS, and an FDA decision on the therapy in nonrelapsing SPMS will ...

A new analysis found that eating both oily fish and wholemeal/wholegrain bread may help lower one's risk of developing ...

If gut bacteria are too similar to the protective layer of nerves, they can misdirect the immune system and cause it to ...

New research shows some gut bacteria mimic myelin, tricking immunity to attack nerves and worsen MS. Non-inflammatory ...

In pediatric-onset multiple sclerosis, switching to oral or infusion therapies was linked to fewer relapses than switching between injectable treatments.

Tolebrutinib failed to meet the primary endpoint in the phase 3 PERSEUS study involving patients with primary progressive multiple sclerosis.

The over-the-counter supplement lipoic acid may have a small beneficial effect in slowing the loss of gray matter in the ...

People typically develop multiple sclerosis between ages 20 and 40, but late-onset MS affects those 50 years and older. Your doctor can best diagnose and advise on possible treatments, such as ...

Elsa Mendoza navigates life with multiple sclerosis, using a wheelchair while her son, Fernando, excels as a quarterback ...